Lv5
880 积分 2021-12-16 加入
感谢科研通大公无私。
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
3天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
7天前
已完结
Ten-Year Follow-Up of Lung Cancer Patients with Resected Stage IA Invasive Non-Small Cell Lung Cancer
8天前
已完结
Site-specific follow-up strategy for surgically resected patients with NSCLC based on ten-year follow-up data
8天前
已完结
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer
10天前
已完结
Association of pretreatment neutrophil-to-lymphocyte ratio with clinical outcomes in cancer immunotherapy: An evidence synthesis from 30 meta-analyses
12天前
已完结
Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia
25天前
已关闭
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma
25天前
已关闭
A temporal perspective for tumor-associated macrophage identities and functions
1个月前
已完结
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy
1个月前
已完结
皖公网安备34019202002308
